Search results
Showing 1301 to 1350 of 2048 results for work
Botulinum toxin type A for preventing episodic migraine [ID6450]
In development Reference number: GID-TA11505 Expected publication date: TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
In development Reference number: GID-TA11606 Expected publication date: TBC
In development Reference number: GID-TA11670 Expected publication date: TBC
In development Reference number: GID-TA11500 Expected publication date: TBC
In development Reference number: GID-TA11299 Expected publication date: TBC
In development Reference number: GID-TA10758 Expected publication date: TBC
In development Reference number: GID-TA11586 Expected publication date: TBC
Discontinued Reference number: GID-TA10196
In development Reference number: GID-TA11690 Expected publication date: TBC
Discontinued Reference number: GID-TAG456
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued Reference number: GID-TA10609
Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]
Discontinued Reference number: GID-TAG431
Discontinued Reference number: GID-TA10185
In development Reference number: GID-TA10608 Expected publication date: TBC
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
In development Reference number: GID-TA11481 Expected publication date: TBC
Clostridium difficile associated diarrhoea - tolevamer [ID378]
Discontinued Reference number: GID-TAG389
In development Reference number: GID-TA11663 Expected publication date: TBC
Discontinued Reference number: GID-TA10390
Abicipar pegol for treating wet age-related macular degeneration [ID1533]
In development Reference number: GID-TA10511 Expected publication date: TBC
In development Reference number: GID-TA10777 Expected publication date: TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Discontinued Reference number: GID-TA10154
In development Reference number: GID-TA10960 Expected publication date: TBC
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Discontinued Reference number: GID-TAG360
Discontinued Reference number: GID-TA10395
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
In development Reference number: GID-TA11368 Expected publication date: TBC
In development Reference number: GID-TA10391 Expected publication date: TBC
Discontinued Reference number: GID-TA10841
In development Reference number: GID-TA11008 Expected publication date: TBC
In development Reference number: GID-TA11801 Expected publication date: TBC
Discontinued Reference number: GID-TA11005
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151
Discontinued Reference number: GID-TA10495
Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]
Discontinued Reference number: GID-TAG482
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Discontinued Reference number: GID-TA10606
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on cyanoacrylate glue for hernia mesh fixation .
Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]
Discontinued Reference number: GID-TAG337
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Discontinued Reference number: GID-TA11228
Discontinued Reference number: GID-TA10072
Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)
NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
In development Reference number: GID-TA11759 Expected publication date: TBC
In development Reference number: GID-TA11607 Expected publication date: TBC
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511